美第奇新星生物技術 MNOV 深 滬
等待開盤 08-10 09:30:00 美东时间
1.34
-0.020
-1.47%
華盛通- 最 高1.3887
- 今 開1.36
- 成交量 1.14万股
- 最 低 1.34
- 昨 收 1.36
- 總市值 6595.65万
- 52周最高 1.96
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 1.168
- 委 比 83.96%
- 總股本 4922.12万
- 歷史最高 14.50
- 量 比 0.35
- 振 幅 3.58%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova announced the successful enrollment of 200 patients in the NIH-funded SEANOBI-ALS study evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS). This milestone reflects strong community engagement and collaboration. The study provides MN-166 to ALS patients ineligible for other trials. Final follow-ups are expected in early 2027, with data analysis to follow. MN-166 is a PDE4 inhibitor and anti-inflammatory compound in la...
07-15 12:00
MediciNova 3000万美元资金支持赢得缓冲时间 如今投资者需要渐冻症相关数据而非空谈
MediciNova通过股权发售协议（SEPA）获得未来36个月内最高3000万美元的普通股融资额度，可按市价的97%向认购方发售股票，动用该额度会产生股权稀释...
06-30 20:29
MediciNova CEO Provides Shareholder Update
MediciNova, Inc. has made significant progress in its key programs, including the completion of the last patient last visit in its Phase 2 clinical trial of MN-001 (tipelukast) for treating hypertriglyceridemia and NAFLD associated with T2DM. The company also expanded its MN-166 (ibudilast) SEANOBI study for ALS, enrolling 100 patients, and received a U.S. patent allowance for ibudilast in combination with anti-PD-1 antibodies for glioblastoma. A...
06-30 12:00
MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma
Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims cover not only the combination of ibudilast with multiple anti-PD-1 antibodies, but also a broad range of treatment
06-08 20:07
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
MediciNova, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering the combination of ibudilast (MN-166) with an anti-PD-1 antibody for glioblastoma treatment. This patent, expected to expire in September 2042, strengthens the company's intellectual property for its combination therapy strategy. MN-166 is in late-stage development for neurodegenerative diseases and other conditions, wit...
06-08 12:00
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova, Inc. has completed the last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for treating hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The study is a multicenter, randomized, double-blind, placebo-controlled trial comparing 500 mg/day of MN-001 to placebo over 24 weeks, with co-primary endpoints of liver fat co...
05-26 23:00
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
A study by CNIO researchers identifies MIF-mediated reprogramming of CD74-positive microglia and macrophages as a key vulnerability in brain metastasis. The research, published in *Cancer Research*, demonstrates that pharmacological modulation of this pathway using ibudilast (MN-166) can suppress metastasis. MediciNova plans to collaborate with CNIO on clinical trials for patients with brain metastases. The findings highlight a new therapeutic ap...
04-27 23:00
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $10.
03-16 19:16
MediciNova to Participate at the 38th Annual ROTH Conference
<p>MediciNova, Inc. announced that its President and CEO, Yuichi Iwaki, M.D., Ph.D., and Chief Business Officer, David H. Crean, Ph.D., will participate in the 38th Annual ROTH Conference on March 22-24, 2026, in Dana Point, CA. They will host investor meetings to provide company updates. The conference will include in-person one-on-one and small group meetings. More details are available at www.roth.com/conferences. MediciNova’s pipeline include...
03-16 11:00
